Regatta Capital Group LLC Has $780,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Regatta Capital Group LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 10.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,393 shares of the company’s stock after selling 529 shares during the period. Regatta Capital Group LLC’s holdings in Johnson & Johnson were worth $780,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co increased its position in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P increased its position in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the period. IFM Investors Pty Ltd grew its position in shares of Johnson & Johnson by 20.1% during the 1st quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock worth $74,259,000 after buying an additional 70,221 shares during the period. Essex LLC grew its position in shares of Johnson & Johnson by 3.7% during the 1st quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after buying an additional 1,146 shares during the period. Finally, PRW Wealth Management LLC grew its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. PRW Wealth Management LLC now owns 2,595 shares of the company’s stock worth $459,000 after buying an additional 210 shares during the period. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock valued at $20,230,174 in the last quarter. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.8 %

NYSE JNJ opened at $176.20 on Friday. The stock has a market capitalization of $460.67 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 3.44 and a beta of 0.57. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business’s fifty day moving average is $167.84 and its 200-day moving average is $171.40.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the business posted $2.60 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson declared that its Board of Directors has approved a stock buyback program on Wednesday, September 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Citigroup reduced their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday. They issued a “neutral” rating and a $170.00 price target for the company. Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.